Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101
Phase of Trial: Phase I/II
Latest Information Update: 31 May 2019
Price : $35 *
At a glance
- Drugs Agenmestencel-T (Primary) ; Ganciclovir
- Indications Adenocarcinoma; Gastrointestinal cancer
- Focus First in man; Proof of concept; Therapeutic Use
- Acronyms TREAT-ME 1
- Sponsors Apceth
- 31 May 2019 Status changed from discontinued to completed.
- 31 May 2019 Results assessing safety and tolerabilty of genetically modified autologous mesenchymal stromal cells published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 23 Mar 2017 Status changed from recruiting to discontinued.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History